Non-small cell lung cancer (NSCLC) is commonly driven by EGFR mutations. Targeted therapies including first-generation tyrosine kinase inhibitors (TKIs), like Gefitinib have been effective; but resistance and tumor heterogeneity remain critical challenges. In this poster, we investigated the molecular and morphological changes in NSCLC cells in response to first- and second- generation TKI therapies using the AVITI24™ platform for high dimensional multomic analysis.
Download this poster to see how AVITI24 provides detailed insights into drug responses and resistance mechanisms. Learn how:
- AVITI24 enables high-resolution, in situ multiplexed analysis of RNA, protein, and cellular morphology with a high correlation to existing low-throughput and time-consuming methods.
- Distinct RNA and protein expression patterns were observed between cells treated with Gefitinib and Osimertinib.
- We identified unique subpopulations with increase in drug dosage or extended incubation time for a better understanding of the holistic impact on entire pathways, including the MAPK pathway.